Ten years ago, InVivo Therapeutics (NASDAQ:NVIV) was spun out of the Massachusetts Institute of Technology with big ambitions and an even bigger amount of chutzpah.
Then-CEO Frank Reynolds was a force of nature, a man we described in a 2009 profile as a “robust 44-year-old who speaks in rapid-fire, Bronx-tinged clips.”
Reynolds left the company in 2013, citing medical reasons, and InVivo Therapeutics moved on with its spinal scaffold device for traumatic spinal cord injuries and is today closer than ever to making a real difference for patients with SCI.
Under new CEO Mark Perrin, InVivo is making great strides. The company has completed enrollment of a 5-patient pilot study with impressive results.
InVivo’s aim is to provide some level of treatment for patients suffering from a spinal cord injury, Perrin told us.
“That is one of the reasons I was so motivated to join InVivo,” he told us. “I can say I’ve never seen a therapeutic space that simply offers nothing for patients.”
In this episode of DeviceTalks, we talk to Perrin about the InVivo story and why there has been so little movement in the fight against paralysis.